A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma

Viatris

Status and phase: Completed; Phase 4

Conditions: Ocular Hypertension; Glaucoma, Open-Angle

Treatments: Drug: Latanoprost

Study type: Interventional

Funder types: Industry

Identifiers

NCT00647101

X-FIL

A6111002

Details and patient eligibility

About

The purpose of this study is to evaluate the effect of latanoprost on intraocular pressure reduction in patients with ocular hypertension or open-angle glaucoma.

Enrollment: 600 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• A patient with an IOP greater than or equal to 20 mmHg related to unilateral or bilateral OH or OAG (primary open angle glaucoma, pseudo-exfoliative glaucoma, and pigmentary glaucoma), after a visual field exam
• Naive patients (i.e. never having been treated) and requiring treatment initiation

Exclusion criteria

• A patient with OH or OAG currently on treatment
• A patient with OH or OAG previously treated (regardless of the date treatment was discontinued)
• A patient with traumatic, inflammatory, or neovascular glaucoma

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

600 participants in 1 patient group

Latanoprost group

Experimental group

Treatment:

Drug: Latanoprost